U.S. markets closed
  • S&P Futures

    3,292.25
    +28.75 (+0.88%)
     
  • Dow Futures

    26,644.00
    +235.00 (+0.89%)
     
  • Nasdaq Futures

    11,227.00
    +94.25 (+0.85%)
     
  • Russell 2000 Futures

    1,551.00
    +11.80 (+0.77%)
     
  • Crude Oil

    37.59
    +0.20 (+0.53%)
     
  • Gold

    1,877.20
    -2.00 (-0.11%)
     
  • Silver

    23.38
    +0.02 (+0.09%)
     
  • EUR/USD

    1.1759
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    0.7810
    +0.0030 (+0.39%)
     
  • Vix

    40.28
    +6.93 (+20.78%)
     
  • GBP/USD

    1.2994
    +0.0007 (+0.06%)
     
  • USD/JPY

    104.4400
    +0.1390 (+0.13%)
     
  • BTC-USD

    13,230.12
    +12.83 (+0.10%)
     
  • CMC Crypto 200

    261.77
    -10.92 (-4.01%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,260.40
    -158.11 (-0.68%)
     

Legend Bio Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Legend Biotech Corporation To Contact The Firm

Newsfile Corp.
·1 min read

New York, New York--(Newsfile Corp. - September 22, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Legend Biotech Corporation ("Legend Bio" or the "Company") (NASDAQ: LEGN).

If you suffered losses exceeding $50,000 investing in Legend Bio stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/LEGN. There is no cost or obligation to you.



You can also contact Faruqi & Faruqi partner James Wilson toll free at 877-247-4292 or 212-983-9330 or by emailing him at jwilson@faruqilaw.com to discuss your rights and options.



Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64337